Clicky

Regeneron Pharmaceuticals, Inc.(REGN) News

Date Title
Jan 7 Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
Jan 6 Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
Jan 2 1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
Jan 1 Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future
Dec 31 Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years
Dec 23 Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Dec 19 Regeneron says study data support big bet on new blood thinners
Dec 19 Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Dec 18 REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Dec 18 Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
Dec 17 Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 17 Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
Dec 17 EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
Dec 17 Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Dec 16 Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
Dec 16 Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
Dec 13 Regeneron Down 15.5% Year to Date: How to Play the Stock?
Dec 13 Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
Dec 12 Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
Sep 30 Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD